Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jun Taguchi

Showing results (141-150 of 154) with videos related to

Pageof 16
Sort By:
Bone Marrow Transplantation|June 13, 2019
Prognostic impact of cytogenetic abnormalities in adult patients with Philadelphia chromosome-negative ALL who underwent an allogeneic transplantHiroaki Shimizu, Noriko Doki, Heiwa Kanamori, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 21, 2018
Clinical Significance of Serum Ferritin at Diagnosis in Patients With Acute Myeloid Leukemia: A YACHT Multicenter Retrospective StudyTakayoshi Tachibana, Taiki Andou, Masatsugu Tanaka, et al.
Leukemia & Lymphoma|June 21, 2016
The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphomaNaoto Tomita, Taisei Suzuki, Kazuho Miyashita, et al.
Cancer Science|September 17, 2020
No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of NagasakiEo Toriyama, Tomoko Hata, Ken-Ichi Yokota, et al.
Leukemia Research|August 23, 2024
Allogeneic stem cell transplant with TBI-based myeloablative conditioning in adolescents and young adults with Philadelphia chromosome-negative ALL treated with pediatric protocolsHiroaki Shimizu, Jun Kato, Susumu Tanoue, et al.
Cancer Science|May 17, 2022
Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma: Phase IIb resultsAtae Utsunomiya, Koji Izutsu, Tatsuro Jo, et al.
Transplantation and Cellular Therapy|May 21, 2026
Treatment outcomes of adult B-cell ALL with post-transplant relapse in the era of immunotherapeutic agentsHiroaki Shimizu, Yuho Najima, Shinichi Kako, et al.
World Journal of Gastroenterology|August 2, 2012
Intraductal neoplasm of the intrahepatic bile duct: clinicopathological study of 24 casesYoshiki Naito, Hironori Kusano, Osamu Nakashima, et al.
International Journal of Hematology|May 4, 2022
Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trialYasushi Miyazaki, Toru Kiguchi, Shinya Sato, et al.
Internal Medicine (Tokyo, Japan)|February 22, 2021
Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study GroupMasahiko Chiwata, Hidehiro Itonaga, Shinya Sato, et al.
Pageof 16

Showing results (141-150 of 154) with videos related to

Sort By:
Pageof 16
Bone Marrow Transplantation|June 13, 2019
Prognostic impact of cytogenetic abnormalities in adult patients with Philadelphia chromosome-negative ALL who underwent an allogeneic transplantHiroaki Shimizu, Noriko Doki, Heiwa Kanamori, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 21, 2018
Clinical Significance of Serum Ferritin at Diagnosis in Patients With Acute Myeloid Leukemia: A YACHT Multicenter Retrospective StudyTakayoshi Tachibana, Taiki Andou, Masatsugu Tanaka, et al.
Leukemia & Lymphoma|June 21, 2016
The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphomaNaoto Tomita, Taisei Suzuki, Kazuho Miyashita, et al.
Cancer Science|September 17, 2020
No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of NagasakiEo Toriyama, Tomoko Hata, Ken-Ichi Yokota, et al.
Leukemia Research|August 23, 2024
Allogeneic stem cell transplant with TBI-based myeloablative conditioning in adolescents and young adults with Philadelphia chromosome-negative ALL treated with pediatric protocolsHiroaki Shimizu, Jun Kato, Susumu Tanoue, et al.
Cancer Science|May 17, 2022
Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma: Phase IIb resultsAtae Utsunomiya, Koji Izutsu, Tatsuro Jo, et al.
Transplantation and Cellular Therapy|May 21, 2026
Treatment outcomes of adult B-cell ALL with post-transplant relapse in the era of immunotherapeutic agentsHiroaki Shimizu, Yuho Najima, Shinichi Kako, et al.
World Journal of Gastroenterology|August 2, 2012
Intraductal neoplasm of the intrahepatic bile duct: clinicopathological study of 24 casesYoshiki Naito, Hironori Kusano, Osamu Nakashima, et al.
International Journal of Hematology|May 4, 2022
Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trialYasushi Miyazaki, Toru Kiguchi, Shinya Sato, et al.
Internal Medicine (Tokyo, Japan)|February 22, 2021
Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study GroupMasahiko Chiwata, Hidehiro Itonaga, Shinya Sato, et al.
Pageof 16